title: Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
abstract: Integrin α(4)β(1) (also called very late antigen-4 or VLA-4) plays an important role in tumor growth, angiogenesis and metastasis, and there has been increasing interest in targeting this receptor for cancer imaging and therapy. In this study, we conjugated a peptidomimetic ligand known to have good binding affinity for α(4)β(1) integrin to a cross-bridged macrocyclic chelator with a methane phosphonic acid pendant arm, CB-TE1A1P. CB-TE1A1P-LLP2A was labeled with (64)Cu under mild conditions in high specific activity, in contrast to conjugates based on the "gold standard" di-acid cross-bridged chelator, CB-TE2A, which require high temperatures for efficient radiolabeling. Saturation binding assays demonstrated that (64)Cu-CB-TE1A1P-LLP2A had comparable binding affinity (1.2 nM vs 1.6 nM) but more binding sites (B(max)=471 fmol/mg) in B16F10 melanoma tumor cells than (64)Cu-CB-TE2A-LLP2A (B(max)=304 fmol/mg, p<0.03). In biodistribution studies, (64)Cu-CB-TE1A1P-LLP2A had less renal retention but higher uptake in tumor (11.4±2.3 %ID/g versus 3.1±0.6 %ID/g, p<0.001) and other receptor-rich tissues compared to(64)Cu-CB-TE2A-LLP2A. At 2h post-injection, (64)Cu-CB-TE1A1P-LLP2A also had significantly higher tumor:blood and tumor:muscle ratios than (64)Cu-CB-TE2A-LLP2A (CB-TE1A1P=19.5±3.0 and 13.0±1.4, respectively, CB-TE2A=4.2±1.4 and 5.5±0.9, respectively, p<0.001). These data demonstrate that (64)Cu-CB-TE1A1P-LLP2A is an excellent PET radiopharmaceutical for the imaging of α(4)β(1) positive tumors and also has potential for imaging other α(4)β(1) positive cells such as those of the pre-metastatic niche.
authors.affiliation: Department of Chemistry, Washington University, St. Louis, Missouri, USA.
authors.forename: Majiong
authors.initials: M
authors.lastname: Jiang
authors.forename: Riccardo
authors.initials: R
authors.lastname: Ferdani
authors.forename: Monica
authors.initials: M
authors.lastname: Shokeen
authors.forename: Carolyn J
authors.initials: CJ
authors.lastname: Anderson
mesh_terms: D000818:Animals; D002614:Chelating Agents / Q000737:chemistry*; D003301:Copper Radioisotopes; D004151:Dipeptides / Q000737:chemistry / Q000378:metabolism* / Q000493:pharmacokinetics; D039041:Integrin alpha4beta1 / Q000378:metabolism*; D008024:Ligands; D047028:Macrocyclic Compounds / Q000737:chemistry*; D008546:Melanoma, Experimental / Q000000981:diagnostic imaging / Q000378:metabolism*; D051379:Mice; D064847:Multimodal Imaging; D057786:Peptidomimetics / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics; D010671:Phenylurea Compounds / Q000737:chemistry / Q000378:metabolism* / Q000493:pharmacokinetics; D049268:Positron-Emission Tomography; D011854:Radiochemistry; D014057:Tomography, X-Ray Computed
chemical_list: D002614:Chelating Agents; D003301:Copper Radioisotopes; D004151:Dipeptides; D039041:Integrin alpha4beta1; C512274:LLP2A compound; D008024:Ligands; D047028:Macrocyclic Compounds; D057786:Peptidomimetics; D010671:Phenylurea Compounds